Story perspectives

FDA Approves RevMed’s Rasonque for Metastatic Pancreatic Cancer

By Drooid · Oct 1, 2026, 2:56 PM UTC · How we work

Summary

Story summary

U.S. FDA approved RevMed’s Rasonque (daraxonrasib) for metastatic pancreatic ductal adenocarcinoma after prior systemic therapy.
A 500-patient trial showed median survival 13.2 months versus 6.7 months, with 1% discontinuation.
Daraxonrasib is the first approved RAS(ON) inhibitor, targeting multiple RAS-mutated cancers.
RevMed’s 2018 acquisition of Warp Drive Bio provided the tri-complex platform that enabled daraxonrasib.

1 of 1

Story summary

U.S. FDA approved RevMed’s Rasonque (daraxonrasib) for metastatic pancreatic ductal adenocarcinoma after prior systemic therapy.
A 500-patient trial showed median survival 13.2 months versus 6.7 months, with 1% discontinuation.
Daraxonrasib is the first approved RAS(ON) inhibitor, targeting multiple RAS-mutated cancers.
RevMed’s 2018 acquisition of Warp Drive Bio provided the tri-complex platform that enabled daraxonrasib.